- Home
- DFDV vs CRBU Comparison
DFDV vs CRBU Comparison
Compare DFDV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFDV | CRBU |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.8M | 203.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DFDV | CRBU |
|---|---|---|
| Price | $6.83 | $1.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $45.00 | $8.50 |
| AVG Volume (30 Days) | ★ 2.0M | 961.5K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | $7,526,660.00 | ★ $9,295,000.00 |
| Revenue This Year | $343.83 | N/A |
| Revenue Next Year | $104.68 | $3.62 |
| P/E Ratio | $1.68 | ★ N/A |
| Revenue Growth | ★ 313.28 | N/A |
| 52 Week Low | $0.53 | $0.66 |
| 52 Week High | $53.88 | $3.54 |
Technical Indicators
Market Signals| Indicator | DFDV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 43.91 |
| Support Level | $6.10 | $1.63 |
| Resistance Level | $7.27 | $1.80 |
| Average True Range (ATR) | 0.62 | 0.08 |
| MACD | 0.33 | 0.02 |
| Stochastic Oscillator | 79.77 | 46.15 |
Price Performance
Historical ComparisonAbout DFDV DeFi Development Corp.
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.